Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 124 results for rheumatoid arthritis

  1. Refractory extrapulmonary sarcoidosis: infliximab (ES4)

    Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

    Evidence summary
    Published
    17 January 2017

  2. Arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis (IPG230)

    Evidence-based recommendations on arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis. This involves flushing the joint with fluid, which is introduced through small incisions in the knee.

    Interventional procedures guidance
    Published
    22 August 2007
    View recommendations

    Sections for IPG230

  3. Committee D members

    Find out more about NICE technology appraisals advisory committee D members

  4. Collaboration between East Staffordshire CCG and Burton Hospitals NHS Foundation Provider Trust Pharmacy Team – Re-design of the management process to comply with NICE Technology Appraisals

    pathway the group created was biologics and targeted therapies in rheumatoid arthritis. Gastroenterology and dermatology are next to be...

    Shared learning
    Last updated
    30 April 2018

  5. Multiple long-term conditions: medication review (IND207)

    This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186

    General practice indicators suitable for use in QOF
    Published
    31 July 2019

  6. Multiple long-term conditions: multimorbidity register (IND205)

    This indicator covers the practice can produce a register of people with multimorbidity who would benefit from a tailored approach to care. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM184

    General practice indicators suitable for use in QOF
    Published
    31 July 2019

  7. Subcutaneous methotrexate:- What is the clinical and cost effectiveness of subcutaneous methotrexate compared with oral methotrexate for adults with early onset RA starting a new DMARD?

    recommendations. Source guidance details Comes from guidance Rheumatoid arthritis in adults: management Number NG100 Date issued

    Research recommendation
    Published
    11 December 2018

  8. Rituximab for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs [ID333]

    Discontinued [GID-TAG418]

    Technology appraisal guidance
    Discontinued

  9. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)

    Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    24 May 2017
    View recommendations

    Sections for TA445

  10. NICE agreed that further research would be of value to investigate factors which can predict the likelihood of rapid progression of disease and response to treatment with biological DMARDs. Factors to investigate include:- persistent elevation of inflammatory markers (such as C-reactive protein [CRP]) and- presence of erosions on X-ray and- positive for anti-citrullinated protein antibodies (ACPA).

    infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or...

    Research recommendation
    Published
    15 March 2016

  11. Metatarsophalangeal joint replacement of the hallux (IPG140)

    Evidence-based recommendations on metatarsophalangeal joint replacement of the hallux. This involves removing the problem joint and replacing it with an artificial one.

    Interventional procedures guidance
    Published
    23 November 2005
    View recommendations

    Sections for IPG140

  12. Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)

    Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making

    Evidence summary
    Published
    21 October 2014

  13. Ultrasound in diagnosis:- What is the clinical and cost effectiveness of using ultrasound in addition to clinical assessment when there is uncertainty about the diagnosis in adults with suspected RA?

    RA. Source guidance details Comes from guidance Rheumatoid arthritis in adults: management Number NG100 Date issued

    Research recommendation
    Published
    11 December 2018

  14. FRAX and QFracture in adults with secondary causes of osteoporosis:- What is the utility of FRAX and QFracture in detecting risk of fragility fracture in adults with secondary causes of osteoporosis?

    risk in patients with causes of secondary osteoporosis other than rheumatoid arthritis and to establish whether their effect on fracture...

    Research recommendation
    Published
    9 June 2015

  15. Management of poor prognosis:- What is the clinical and cost effectiveness of managing RA with a poor prognosis (identified as presence of anti-cyclic citrullinated peptide [CCP] antibodies or evidence of erosions on X-ray at diagnosis) with a different strategy from that used for standard management of RA?

    group. Source guidance details Comes from guidance Rheumatoid arthritis in adults: management Number NG100 Date issued

    Research recommendation
    Published
    11 December 2018